Evidence map›Paper›PMID 17540031›Full record

ArticleBMC microbiology2007

M. tuberculosis genotypic diversity and drug susceptibility pattern in HIV-infected and non-HIV-infected patients in northern Tanzania.

Gibson S Kibiki, Bert Mulder, Wil M V Dolmans, Jessica L de Beer, Martin Boeree, Noel Sam, Dick van Soolingen, Christophe Sola, Adri G M van der Zanden

Registry-linked trialAbstract read
In one paragraph

Article in BMC microbiology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00760149 (Pharmacokinetics and Pharmacodynamics of High Versus Standard Dose Rifampicin in Patients With Pulmonary Tuberculosis in the Kilimanjaro Region, Tanzania.), which is not on this map. Cited by 35 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00760149 phase2completednot on this mapstarted 2010, after this paper: background citation

Pharmacokinetics and Pharmacodynamics of High Versus Standard Dose Rifampicin in Patients With Pulmonary Tuberculosis in the Kilimanjaro Region, Tanzania.

TypeinterventionalSponsorRadboud University Medical CenterRan2010 to 2013Enrolled150ConditionsTuberculosisArmsRifampicin in higher doses
3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Trial
  4. Genetic diversity ofNew microbes and new infections · 2024
    Article
  5. Article
  6. Article
  7. Resistance ofHeliyon · 2019
    Article
  8. Article
  9. Diversity ofBioMed research international · 2018
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Gibson S KibikiDepartment of Internal Medicine, Endoscopy Unit, Kilimanjaro Christian Medical Centre, Tumaini University, Moshi, Tanzania. gkibiki@gmail.com <gkibiki@gmail.com>
Bert Mulder
Wil M V Dolmans
Jessica L de Beer
Martin Boeree
Noel Sam
Dick van Soolingen
Christophe Sola
Adri G M van der Zanden

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTuberculosis (TB) is a major health problem and HIV is the major cause of the increase in TB. Sub-Saharan Africa is endemic for both TB and HIV infection. Determination of the prevalence of M. tuberculosis strains and their drug susceptibility is important for TB control.TB positive culture, BAL fluid or sputum samples from 130 patients were collected and genotyped. The spoligotypes were correlated with anti-tuberculous drug susceptibility in HIV-infected and non-HIV patients from Tanzania.

resultsOne-third of patients were TB/HIV co-infected. Forty-seven spoligotypes were identified. Fourteen isolates (10.8%) had new and unique spoligotypes while 116 isolates (89.2%) belonged to 33 known spoligotypes. The major spoligotypes contained nine clusters: CAS1-Kili 30.0%, LAM11- ZWE 14.6%, ND 9.2%, EAI 6.2%, Beijing 5.4%, T-undefined 4.6%, CAS1-Delhi 3.8%, T1 3.8% and LAM9 3.8%. Twelve (10.8%) of the 111 phenotypically tested strains were resistant to anti-TB drugs. Eight (7.2%) were monoresistant strains: 7 to isoniazid (INH) and one to streptomycin. Four strains (3.5%) were resistant to multiple drugs: one (0.9%) was resistant to INH and streptomycin and the other three (2.7%) were MDR strains: one was resistant to INH, rifampicin and ethambutol and two were resistant to all four anti-TB drugs. Mutation in the katG gene codon 315 and the rpoB hotspot region showed a low and high sensitivity, respectively, as predictor of phenotypic drug resistance.

conclusionCAS1-Kili and LAM11-ZWE were the most common families. Strains of the Beijing family and CAS1-Kili were not or least often associated with resistance, respectively. HIV status was not associated with spoligotypes, resistance or previous TB treatment.

Indexed as

Drug Resistance, BacterialAdultAntitubercular AgentsBacterial ProteinsBacterial Typing TechniquesBronchoalveolar Lavage FluidCatalaseCluster AnalysisDNA, BacterialDNA-Directed RNA PolymerasesDrug Resistance, Multiple, BacterialFemaleGenotypeHIV InfectionsHumansMaleAntitubercular AgentsBacterial ProteinsCatalaseDNA, BacterialDNA-Directed RNA PolymeraseskatG protein, Mycobacterium tuberculosisRNA polymerase beta subunit

Identifiers

PMID17540031
PMCPMC1913919

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.